ReviewDrugs & aging2026
Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives.
Review in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Effects of Neurotropic B Vitamins, Vitamin D3, and Alpha-Lipoic Acid in In Vitro Models of Neurodegeneration.Nutrients · 2026Article
- Neuroprotective Effects of Choline Alfoscerate in Experimental Diabetic Peripheral Neuropathy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Bone‑origin repair in diabetic foot ulcers: Mechanisms of callus formation and endocrine effects in healing (Review).International journal of molecular medicine · 2026Review
- Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.Bioactive materials · 2026Review
- Review
- Changes in tactile acuity and their association with balance impairment in type 2 diabetes: A 2-year cohort study.Diabetology & metabolic syndrome · 2026Article
- Modulating the Gut-Nerve Axis and Inflammation: A Narrative Review of Dietary Patterns in Diabetic Peripheral Neuropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Diabetic Neuropathy: From Etiopathogenesis to Integrative Therapeutic Strategies with Traditional Chinese Medicine.International journal of general medicine · 2026Review
- Modulation of ion channels as emerging therapeutic targets in the treatment of diabetic neuropathy.EXCLI journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetic peripheral neuropathy (DPN) is one of the most significant chronic complications in people with diabetes. It is a highly heterogeneous condition that affects various parts of the nervous system and presents with a wide range of symptoms. Early diagnosis of diabetic neuropathy is possible if regular screening for this complication is conducted using modern diagnostic methods. Every diabetes clinic should perform annual screening for DPN to identify the risk of diabetic foot disease using a monofilament and tuning fork (or biothesiometer). The treatment of diabetic neuropathy remains limited, as studies on causal therapy have shown conflicting results. In most cases, treatment is restricted to achieving optimal glucose control, symptomatic therapy and the management of the painful form of diabetic neuropathy. Ultimately prevention of complications secondary to neuropathy is paramount and it can lead to foot ulcerations, deformities and amputations.Diabetic neuropathy represents a major health challenge for individuals with diabetes, necessitating ongoing research and public health initiatives aimed at improving screening, prevention and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.